Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 9/20 | 0.34 |
| ▸ | JAK1 | P23458 | 9/20 | 0.34 |
| ▸ | TYK2 | P29597 | 9/20 | 0.34 |
| ▸ | JAK3 | P52333 | 9/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 3/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26452680 | 0.87 | GABRA1 (0.31) | GABRA1GABRG2GABRB3 | |
| SCHEMBL26452673 | 0.86 | ACHE (0.31) | CSNK2A1 | |
| SCHEMBL24896997 | 0.79 | GRIA2 (0.36) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL22432099 | 0.78 | LRRK2 (0.32) | — | |
| SCHEMBL26456398 | 0.77 | GABRA1 (0.30) | GABRA1GABRG2GABRB3 | |
| SCHEMBL26452714 | 0.73 | MPO (0.46) | — | |
| SCHEMBL17755708 | 0.73 | GRIA2 (0.30) | — | |
| SCHEMBL26452723 | 0.72 | LRRK2 (0.42) | JAK2 | |
| SCHEMBL26051307 | 0.72 | IRAK4 (0.32) | — | |
| SCHEMBL24896994 | 0.71 | MPO (0.47) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858912-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858912-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | JAK2 519/4885JAK1 874/4885TYK2 1759/4885 |
| US-20230133845-A1 | NOVEL HETEROCYCLIC COMPOUNDS | F12, PM20D2, XDH | JAK2 720/4885JAK1 890/4885TYK2 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.